2020 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2020 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2020 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2022 (v1)Publication
: Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged but might be challenging. Oncofertility counseling should be offered at the time of diagnosis to all patients, in order to inform them about the...
Uploaded on: February 4, 2024 -
2022 (v1)Publication
The study of circulating cancer-derived components (circulome) is considered the new frontier of liquid biopsy. Despite the recognized role of circulome biomarkers, their comparative molecular profiling is not yet routine. In advanced breast cancer (BC), approximately 40% of hormone-receptor-positive, HER2-negative BC cases harbor druggable...
Uploaded on: January 31, 2024 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Introduction: The prognosis of patients with HER2-positive early breast cancer has radically improved after the introduction of (neo)adjuvant anti-HER2 targeted therapy. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining the anticancer properties of the anti-HER2 agent trastuzumab and the antineoplastic cytotoxic drug DM1....
Uploaded on: April 14, 2023 -
2023 (v1)Publication
No description
Uploaded on: February 13, 2024 -
2023 (v1)Publication
: In patients with early breast cancer, the combination of different systemic treatment strategies, including chemotherapy, endocrine therapy, targeted therapy, and more recently also immunotherapy has demonstrated to significantly improve their survival outcomes. However, this gain is often obtained at the cost of higher toxicity calling for...
Uploaded on: February 4, 2024 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2024 (v1)Publication
IntroductionAnticancer treatments have significantly contributed to increasing cure rates of breast cancer in the last years; however, they can also lead to short- and long-term side effects, including gonadotoxicity, and compromised fertility in young women. Oncofertility is a crucial issue for young patients who have not yet completed their...
Uploaded on: October 13, 2024 -
2023 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2024 (v1)Publication
Background: Intermediate clinical endpoints (ICEs) are frequently used as primary endpoint in randomised trials (RCTs). We aim to assess whether changes in different ICEs can be used to predict changes in overall survival (OS) in adjuvant breast cancer trials. Methods: Individual patient level data from adjuvant phase III RCTs conducted by the...
Uploaded on: July 3, 2024 -
2023 (v1)Publication
Background: Treatment options for advanced melanoma have increased with the US Food and Drug Administration approval of the anti-LAG3 plus anti-PD-1 relatlimab/ nivolumab combination. To date, ipilimumab/nivolumab is the benchmark of overall survival, despite a high toxicity profile. Furthermore, in BRAF-mutant patients, BRAF/MEK in-hibitors...
Uploaded on: February 4, 2024 -
2023 (v1)Publication
Introduction: Breast cancer is the most commonly diagnosed malignancy during pregnancy. Breast cancer during pregnancy is a challenging clinical condition requiring proper and timely multidisciplinary management. Areas covered: This review focuses on the management of breast cancer during pregnancy with a focus about the current...
Uploaded on: September 11, 2024